+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 99Years
All Genders
ID06467357

Phase 3 Trial Comparing Trastuzumab Deruxtecan with or without Rilvegostomig Against Standard Chemotherapy and Durvalumab for Advanced HER2-Positive Biliary Tract Cancer

Led by AstraZeneca · Updated on 2026-10-13

620

Participants Needed

272

Research Sites

48 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of trastuzumab deruxtecan T-DXd combined with rilvegostomig, and T-DXd alone, compared with the standard treatment of gemcitabine, cisplatin, and durvalumab for patients with advanced, untreated HER2-expressing biliary tract cancer. This Phase 3 study focuses on patients with locally advanced or metastatic disease, aiming to compare overall survival and other outcomes across different treatment groups. Participants are assigned to one of three groups one receiving T-DXd and rilvegostomig together, another receiving T-DXd alone, and a third receiving the standard care of gemcitabine, cisplatin, and durvalumab. All treatments are given by intravenous infusion. The study includes an initial safety run-in phase followed by a randomized portion where patients receive assigned treatments until disease progression or other criteria are met. The study is estimated to continue for up to 50 months after the first patient is randomized. During the trial, participants will have tumor samples collected, and their disease will be monitored through imaging and clinical assessments. Researchers will evaluate safety, tolerability, overall survival, progression-free survival, response rates, and patient-reported outcomes like side effects and physical functioning. Blood samples will be taken to study drug levels and immune responses. The study plans to follow participants for long-term outcomes and side effects, with regular visits scheduled throughout the study duration.

CONDITIONS

Brief Title

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here